Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia

Table 1 Baseline demographic, laboratory, and clinical features

Baseline feature	Randomized treatment assignment			p-value	Historic relapse control
Baseline feature	AS + PQ	AS-PYR + PQ	DHA-PP + PQ	p-value	AS alone
Subjects	60	60	60	--	41
Mean age (range)	29.4 (25–45)	28.6 (21–45)	29.5 (23–50)	0.54	27.7 (22–39)
Mean kg weight (range)	69 (55–87)	71 (54–88)	67 (52–88)	0.05	67 (52–90)
Tympanic °C
Mean	37.1	37.3	37.2	0.37	36.7
Mean g/dL
Hemoglobin	13.8	13.9	13.5	0.54	14.2
Mean %
Methemoglobin	1.39	1.42	1.46	0.35	1.48
Median parasites/μL blood (range)	744 (16–7664)	888 (32–6016)	880 (16–9488)	0.94	1408 (32–15248)
WBCs × 10³/μL	7051	6886	6945	0.66	7700
Platelets × 10³/μL	171	166	161	0.75	167
Glucose mg/dL	106	108	103	0.73	108
Bilirubin mg/dL	1.03	0.97	1.04	0.69	1.08

AS artesunate, PQ primaquine, PYR pyronaridine, DHA-PP dihydroartemisinin-piperaquine

ISSN: 1741-7015